Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017

This report provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervical Cancer, Vaginal Cancer and Vulvar Cancer, and features dormant and discontinued projects.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia, is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aged from 25 to 35. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). Vaginal cancer is a rare cancer that causes symptoms such as watery vaginal discharge, a lump or mass in the vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Finally, Vulvar cancer is another rare type of cancer. It forms in a woman’s external genitals, called the vulva.

The size of these pipelines ranges from five and six products in vulvar and vaginal cancer respectively to 163 in cervical cancer. The most prominent targets in the cervical cancer pipeline are HPV proteins there are a number of products in the pipeline targeting HPV protein E7 and HPV protein E6. Other common targets in the pipeline include vascular endothelial growth factor A and programmed cell death protein 1.

Scope

– Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?

– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

– What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Companies mentioned

Abion Inc

Abivax SA

Admedus Ltd

Advaxis Inc

Advenchen Laboratories LLC

Agenus Inc

Amgen Inc

AntiCancer Inc

Antigen Express Inc

Arbor Vita Corp

ArQule Inc

Asana BioSciences LLC

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Bayer AG

BeiGene Ltd

Bioleaders Corp

Biomics Biotechnologies Co Ltd

Blirt SA

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

Cancer Research Technology Ltd

Celleron Therapeutics Ltd

Cervical Cancer

Coherus BioSciences Inc

Critical Outcome Technologies Inc

Cutanea Life Sciences Inc

Cytori Therapeutics Inc

CZ BioMed Corp

DelMar Pharmaceuticals Inc

Dr. Reddy’s Laboratories Ltd

Eisai Co Ltd

Etubics Corp

Eureka Therapeutics Inc

EyeGene Inc

F. Hoffmann-La Roche Ltd

Formune SL

GamaMabs Pharma SA

Gene Techno Science Co Ltd

Genentech Inc

Genmab A/S

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

Glycostem Therapeutics BV

Glycotope GmbH

Gradalis Inc

Immunomedics Inc

Immunovaccine Inc

Innate Pharma SA

Innovation Pharmaceuticals Inc

Iovance Biotherapeutics Inc

ISA Pharmaceuticals BV

Johnson & Johnson

Juno Therapeutics Inc

Kaketsuken

Karyopharm Therapeutics Inc

Kite Pharma Inc

LondonPharma Ltd

Mabion SA

MedImmune LLC

Merck & Co Inc

Merck KGaA

Mycenax Biotech Inc

Nektar Therapeutics

NeoImmuneTech Inc

Ology Bioservices Inc

Oncobiologics Inc

Ono Pharmaceutical Co Ltd

Oryx GmbH & Co KG

PDS Biotechnology Corp

Pfizer Inc

Pharma Mar SA

Psicofarma SA de CV

Puma Biotechnology Inc

Regeneron Pharmaceuticals Inc

Rexahn Pharmaceuticals Inc

Richter Gedeon Nyrt

Samyang Holdings Corp

Sanofi

Seattle Genetics Inc

Selecta Biosciences Inc

Shantha Biotechnics Pvt Ltd

Sirnaomics Inc

Sun Pharma Advanced Research Company Ltd

Taiwan Liposome Company Ltd

Tessa Therapeutics Pte Ltd

Theralase Technologies Inc

Theravectys SA

THEVAX Genetics Vaccine USA Inc

UbiVac LLC

Vectorite Biomedica Inc

VLPbio

Wellstat Biologics Corp

Zeria Pharmaceutical Co Ltd

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 5

1.2 List of Figures 7

2 Introduction 8

2.1 Lower Female Reproductive System Cancers Report Coverage 8

2.2 Cervical Cancer – Overview 8

2.3 Vaginal Cancer – Overview 8

2.4 Vulvar Cancer – Overview 8

3 Therapeutics Development 9

3.1 Cervical Cancer 9

3.2 Vaginal Cancer 24

3.3 Vulvar Cancer 27

4 Therapeutics Assessment 30

4.1 Cervical Cancer 30

4.2 Vaginal Cancer 42

4.3 Vulvar Cancer 48

5 Companies Involved in Therapeutics Development 54

5.1 Cervical Cancer 54

5.2 Vaginal Cancer 100

5.3 Vulvar Cancer 103

6 Dormant Projects 106

6.1 Cervical Cancer 106

6.2 Vaginal Cancer 110

6.3 Vulvar Cancer 110

7 Discontinued Products 111

7.1 Cervical Cancer 111

8 Product Development Milestones 112

8.1 Cervical Cancer 112

8.2 Vulvar Cancer 125

9 Appendix 128

9.1 Methodology 128

9.2 Coverage 128

9.3 Secondary Research 128

9.4 Primary Research 128

9.5 Expert Panel Validation 128

9.6 Contact Us 129

9.7 Disclaimer 129

List of Tables

1.1 List of Tables

Table 1: Number of Products under Development for Cervical Cancer 9

Table 2: Number of Products under Development by Companies, Cervical Cancer 11

Table 3: Number of Products under Development by Universities/Institutes, Cervical Cancer 15

Table 4: Products under Development by Companies, Cervical Cancer 16

Table 5: Products under Development by Universities/Institutes, Cervical Cancer 22

Table 6: Number of Products under Development for Vaginal Cancer 24

Table 7: Number of Products under Development by Companies, Vaginal Cancer 25

Table 8: Products under Development by Companies, Vaginal Cancer 26

Table 9: Number of Products under Development for Vulvar Cancer 27

Table 10: Number of Products under Development by Companies, Vulvar Cancer 28

Table 11: Products under Development by Companies, Vulvar Cancer 29

Table 12: Number of Products by Stage and Target, Cervical Cancer 31

Table 13: Number of Products by Stage and Mechanism of Action, Cervical Cancer 35

Table 14: Number of Products by Stage and Route of Administration, Cervical Cancer 39

Table 15: Number of Products by Stage and Molecule Type, Cervical Cancer 41

Table 16: Number of Products by Stage and Target, Vaginal Cancer 43

Table 17: Number of Products by Stage and Mechanism of Action, Vaginal Cancer 44

Table 18: Number of Products by Stage and Route of Administration, Vaginal Cancer 46

Table 19: Number of Products by Stage and Molecule Type, Vaginal Cancer 47

Table 20: Number of Products by Stage and Target, Vulvar Cancer 49

Table 21: Number of Products by Stage and Mechanism of Action, Vulvar Cancer 50

Table 22: Number of Products by Stage and Route of Administration, Vulvar Cancer 52

Table 23: Number of Products by Stage and Molecule Type, Vulvar Cancer 53

Table 24: Cervical Cancer – Pipeline by Abion Inc 54

Table 25: Cervical Cancer – Pipeline by Abivax SA 54

Table 26: Cervical Cancer – Pipeline by Admedus Ltd 55

Table 27: Cervical Cancer – Pipeline by Advaxis Inc 55

Table 28: Cervical Cancer – Pipeline by Advenchen Laboratories LLC 56

Table 29: Cervical Cancer – Pipeline by Agenus Inc 56

Table 30: Cervical Cancer – Pipeline by Amgen Inc 57

Table 31: Cervical Cancer – Pipeline by AntiCancer Inc 57

Table 32: Cervical Cancer – Pipeline by Antigen Express Inc 58

Table 33: Cervical Cancer – Pipeline by Arbor Vita Corp 58

Table 34: Cervical Cancer – Pipeline by ArQule Inc 59

Table 35: Cervical Cancer – Pipeline by Asana BioSciences LLC 59

Table 36: Cervical Cancer – Pipeline by AstraZeneca Plc 60

Table 37: Cervical Cancer – Pipeline by AVEO Pharmaceuticals Inc 60

Table 38: Cervical Cancer – Pipeline by Bayer AG 61

Table 39: Cervical Cancer – Pipeline by BeiGene Ltd 62

Table 40: Cervical Cancer – Pipeline by Bioleaders Corp 62

Table 41: Cervical Cancer – Pipeline by Biomics Biotechnologies Co Ltd 62

Table 42: Cervical Cancer – Pipeline by Blirt SA 63

Table 43: Cervical Cancer – Pipeline by Boehringer Ingelheim GmbH 63

Table 44: Cervical Cancer – Pipeline by Bristol-Myers Squibb Co 64

Table 45: Cervical Cancer – Pipeline by Cadila Healthcare Ltd 64

Table 46: Cervical Cancer – Pipeline by Cancer Research Technology Ltd 65

Table 47: Cervical Cancer – Pipeline by Celleron Therapeutics Ltd 65

Table 48: Cervical Cancer – Pipeline by Coherus BioSciences Inc 66

Table 49: Cervical Cancer – Pipeline by Critical Outcome Technologies Inc 66

Table 50: Cervical Cancer – Pipeline by Cytori Therapeutics Inc 67

Table 51: Cervical Cancer – Pipeline by CZ BioMed Corp 67

Table 52: Cervical Cancer – Pipeline by DelMar Pharmaceuticals Inc 68

Table 53: Cervical Cancer – Pipeline by Dr. Reddy’s Laboratories Ltd 68

Table 54: Cervical Cancer – Pipeline by Eisai Co Ltd 69

Table 55: Cervical Cancer – Pipeline by Etubics Corp 69

Table 56: Cervical Cancer – Pipeline by Eureka Therapeutics Inc 70

Table 57: Cervical Cancer – Pipeline by EyeGene Inc 70

Table 58: Cervical Cancer – Pipeline by F. Hoffmann-La Roche Ltd 71

Table 59: Cervical Cancer – Pipeline by Formune SL 71

Table 60: Cervical Cancer – Pipeline by GamaMabs Pharma SA 72

Table 61: Cervical Cancer – Pipeline by Gene Techno Science Co Ltd 72

Table 62: Cervical Cancer – Pipeline by Genentech Inc 73

Table 63: Cervical Cancer – Pipeline by Genmab A/S 73

Table 64: Cervical Cancer – Pipeline by Genor BioPharma Co Ltd 74

Table 65: Cervical Cancer – Pipeline by GlaxoSmithKline Plc 74

Table 66: Cervical Cancer – Pipeline by Glycostem Therapeutics BV 75

Table 67: Cervical Cancer – Pipeline by Glycotope GmbH 75

Table 68: Cervical Cancer – Pipeline by Gradalis Inc 76

Table 69: Cervical Cancer – Pipeline by Immunomedics Inc 76

Table 70: Cervical Cancer – Pipeline by Immunovaccine Inc 77

Table 71: Cervical Cancer – Pipeline by Innate Pharma SA 77

Table 72: Cervical Cancer – Pipeline by Innovation Pharmaceuticals Inc 78

Table 73: Cervical Cancer – Pipeline by Iovance Biotherapeutics Inc 78

Table 74: Cervical Cancer – Pipeline by ISA Pharmaceuticals BV 79

List of Figures

1.2 List of Figures

Figure 1: Number of Products under Development for Cervical Cancer 9

Figure 2: Number of Products under Development by Companies, Cervical Cancer 10

Figure 3: Number of Products under Development by Universities/Institutes, Cervical Cancer 14

Figure 4: Number of Products under Development for Vaginal Cancer 24

Figure 5: Number of Products under Development by Companies, Vaginal Cancer 25

Figure 6: Number of Products under Development for Vulvar Cancer 27

Figure 7: Number of Products under Development by Companies, Vulvar Cancer 28

Figure 8: Number of Products by Top 10 Targets, Cervical Cancer 30

Figure 9: Number of Products by Stage and Top 10 Targets, Cervical Cancer 30

Figure 10: Number of Products by Top 10 Mechanism of Actions, Cervical Cancer 34

Figure 11: Number of Products by Stage and Top 10 Mechanism of Actions, Cervical Cancer 34

Figure 12: Number of Products by Routes of Administration, Cervical Cancer 38

Figure 13: Number of Products by Stage and Routes of Administration, Cervical Cancer 39

Figure 14: Number of Products by Top 10 Molecule Types, Cervical Cancer 40

Figure 15: Number of Products by Stage and Top 10 Molecule Types, Cervical Cancer 40

Figure 16: Number of Products by Targets, Vaginal Cancer 42

Figure 17: Number of Products by Stage and Targets, Vaginal Cancer 42

Figure 18: Number of Products by Mechanism of Actions, Vaginal Cancer 43

Figure 19: Number of Products by Stage and Mechanism of Actions, Vaginal Cancer 44

Figure 20: Number of Products by Routes of Administration, Vaginal Cancer 45

Figure 21: Number of Products by Stage and Routes of Administration, Vaginal Cancer 45

Figure 22: Number of Products by Molecule Types, Vaginal Cancer 46

Figure 23: Number of Products by Stage and Molecule Types, Vaginal Cancer 47

Figure 24: Number of Products by Targets, Vulvar Cancer 48

Figure 25: Number of Products by Stage and Targets, Vulvar Cancer 48

Figure 26: Number of Products by Mechanism of Actions, Vulvar Cancer 49

Figure 27: Number of Products by Stage and Mechanism of Actions, Vulvar Cancer 50

Figure 28: Number of Products by Routes of Administration, Vulvar Cancer 51

Figure 29: Number of Products by Stage and Routes of Administration, Vulvar Cancer 51

Figure 30: Number of Products by Molecule Types, Vulvar Cancer 52

Figure 31: Number of Products by Stage and Molecule Types, Vulvar Cancer 53

    Pricing

Quick Buy
Add to basket Request sample pages

Discounts available for multiple purchases.

reportstore@marketline.com
+44 20 7947 2960

Saved reports